Edwards Lifesciences (EW) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 7, 2026, to be held virtually for shareholders of record as of March 10, 2026.

• Proxy materials, including the Notice of Meeting, Proxy Statement, and 2025 Annual Report/Form 10-K, are available online, with options for paper or email delivery upon request.

Voting matters and shareholder proposals

• Shareholders will vote on the election of nine directors.

• Advisory vote on named executive officer compensation (say-on-pay) is included.

• Ratification of the appointment of the independent registered public accounting firm is on the agenda.

• Approval of the amended and restated long-term stock incentive compensation program will be considered.

Board of directors and corporate governance

• Board recommends a vote for all proposals presented, including the full slate of director nominees.

• Director nominees include Leslie C. Davis, David T. Feinberg, Kieran T. Gallahue, Leslie S. Heisz, Paul A. LaViolette, Steven R. Loranger, Ramona Sequeira, Nicholas J. Valeriani, and Bernard Zovighian.